Market Closed -
Nasdaq
21:00:00 17/07/2024 BST
5-day change
1st Jan Change
149.2
USD
-1.70%
+7.72%
+89.07%
Presenter SpeechK. Gong (Analysts)Okay. Hello, everyone. Welcome to the last session of Wednes...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Transmedics Group Insider Sold Shares Worth $1,252,051, According to a Recent SEC Filing
07-17
MT
Piper Sandler Adjusts TransMedics Group's PT to $170 From $120, Keeps Overweight Rating
07-15
MT
Morgan Stanley Boosts Price Target on TransMedics Group to $145 From $104, Keeps Equalweight Rating
07-15
MT
CL King Initiates TransMedics at Buy Rating With $161 Price Target
06-07
MT
Transmedics Group Insider Sold Shares Worth $393,986, According to a Recent SEC Filing
06-05
MT
Transmedics Group Insider Sold Shares Worth $280,016, According to a Recent SEC Filing
06-05
MT
Stephens Initiates TransMedics at Overweight Rating With $151 Price Target
06-04
MT
Stephens Starts TransMedics Group With Overweight Rating, $151 Price Target
06-04
MT
Transmedics Group Insider Sold Shares Worth $3,902,100, According to a Recent SEC Filing
05-08
MT
Transmedics Group Insider Sold Shares Worth $759,479, According to a Recent SEC Filing
05-08
MT
Transmedics Group Insider Sold Shares Worth $930,278, According to a Recent SEC Filing
05-08
MT
Transmedics Group Insider Sold Shares Worth $1,920,000, According to a Recent SEC Filing
05-08
MT
Transmedics Group Insider Sold Shares Worth $7,986,219, According to a Recent SEC Filing
05-03
MT
Transmedics Group Insider Sold Shares Worth $1,600,633, According to a Recent SEC Filing
05-03
MT
TransMedics Group Shares Rise as Q1 Swings to Net Income, Revenue Rises; Increases 2024 Revenue Outlook
05-01
MT
Oppenheimer Adjusts TransMedics Group Price Target to $125 From $105, Maintains Outperform Rating
05-01
MT
Earnings Flash (TMDX) TRANSMEDICS GROUP Posts Q1 Revenue $96.9M, vs. Street Est of $83.8M
04-30
MT
TransMedics Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
04-30
CI
Transcript : TransMedics Group, Inc., Q1 2024 Earnings Call, Apr 30, 2024
04-30
TransMedics Group, Inc. Raises Revenue Guidance for the Full Year 2024
04-30
CI
Transmedics Group Insider Sold Shares Worth $380,480, According to a Recent SEC Filing
04-18
MT
Transmedics Group Insider Sold Shares Worth $802,084, According to a Recent SEC Filing
04-05
MT
Transmedics Group Insider Sold Shares Worth $1,110,150, According to a Recent SEC Filing
04-02
MT
Piper Sandler Initiates TransMedics Group With Overweight Rating, $95 Price Target
03-28
MT
Oppenheimer Adjusts TransMedics Group Price Target to $105 From $92, Maintains Outperform Rating
02-27
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ retrieval, OCS organ management and logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation, ground transportation and other coordination activity. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
More about the company
Last Close Price
151.8
USD
Average target price
146.4
USD
Spread / Average Target
-3.58%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1